Burning Rock Biotech (BNR) Short term Debt (2019 - 2025)

Burning Rock Biotech (BNR) recorded quarterly Short term Debt of $28198.5 in Q4 2025, up 0.71% quarter-over-quarter from $28000.0 in Q2 2025.

Burning Rock Biotech (BNR) Short term Debt (2019 - 2025) Analysis & Trends

Burning Rock Biotech's Short term Debt history runs 4 years deep, the most recent figure standing at $28198.5 for Q4 2025.

In Q4 2025, Short term Debt changed N/A year-over-year to $28198.5; the TTM figure through Dec 2025 stood at $28198.5 (changed N/A YoY), while the FY2025 annual figure was $29000.0, changed N/A from the prior year.
Short term Debt was $28198.5 for Q4 2025 at Burning Rock Biotech, up from $28000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $5.0 million in Q1 2021 to a low of $28000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	30,529.42 Bn	30,528.96 Bn	1.11 Bn
2	Thermo Fisher Scientific	183.75 Bn	180.50 Bn	7.74 Bn
3	Danaher	133.13 Bn	127.43 Bn	3.59 Bn
4	Idexx Laboratories	46.14 Bn	45.94 Bn	722.74 Mn
5	Agilent Technologies	38.20 Bn	36.39 Bn	990.00 Mn
6	Natera	31.50 Bn	30.40 Bn	696.04 Mn
7	Iqvia Holdings	31.34 Bn	29.36 Bn	1.36 Bn
8	Illumina	24.51 Bn	23.36 Bn	721.00 Mn
9	Mettler Toledo International	23.53 Bn	23.47 Bn	555.82 Mn
10	Burning Rock Biotech	20.64 Mn	-47.19 Mn	14.10 Mn

Download Data